More recently, BKT140, a highly selective inverse agonist of CXCR4, was shown to reduce the colony-forming capacity of NSCLC cell lines in vitro, and the growth of NSCLC cell line xenografts in vivo [104]. This evidence concerns the gene CXCR4 and non-small cell lung carcinoma.